BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Tetracore Inc. Release: First FDA Cleared Laboratory Test For Anthrax


10/19/2005 5:09:33 PM

GAITHERSBURG, Md., Dec. 18 /PRNewswire/ -- Tetracore, Inc. announced today, December 18, 2003, that it has received 510(K) clearance from the Food and Drug Administration (FDA) for RedLine Alert(TM), an antibody-based test kit for use as an aid in the clinical laboratory identification of Bacillus anthracis colonies from culture plates. B. anthracis is the causative agent of anthrax. The test is a lateral flow immunoassay containing a monoclonal antibody which is specific for the presence of a cell surface protein found in Bacillus anthracis vegetative cells. The test can be used on colonies as early as 12 hours old. Attended time takes as little as 10 minutes and the test can be fully completed within 20 minutes. In data submitted to the FDA on 145 Bacillus anthracis isolates, the RedLine Alert % correct was 98.6%; these isolates originated from 28 countries world-wide. This compared favorably to another well recognized confirmatory test called gamma phage lysis, which can require an additional day of culture to perform, whose % correct was 97.2%. In addition, the RedLine Alert(TM) Test had an accuracy of 100% in correctly differentiating B. anthracis from forty-nine other non-hemolytic Bacillus. Dr. Beverly L. Mangold of Tetracore commented, "We are excited to be able to provide a significant new clinical and public health tool to aid in protecting against bio-terrorism threats."

Tetracore wishes to thank the following organizations for their help in evaluation of this test. Brigham Young University, Department of Microbiology (Dr. Richard Robison); U.S. Army Medical Research Institute of Infectious Diseases (Dr. John Ezzell); Wadsworth Center, New York State Department of Health (Dr. Nick Cirino); Los Alamos National Laboratory (Dr. Paul Jackson), Florida Department of Health Bureau of Laboratories - Miami (Dr. Segaran P. Pillai), St. Michael's Hospital Toronto, Canada (Dr. H. Roslyn Devlin), North Shore - Long Island Jewish Health System Laboratories (Dr. Christine C. Ginocchio), and Driscoll Childrens Hospital Microbiology Department, Corpus Christi, Texas (Ms. Pam Zapalac).

The FDA press release regarding RedLine Alert(TM) can be found at http://www.fda.gov/bbs/topics/NEWS/2003/NEW00992.html

About Tetracore, Inc.

Tetracore is a biotechnology R&D and product company whose mission is to create and develop highly innovative diagnostic reagents and assays for infectious diseases and bio-terrorism threat agents. Areas of company focus include clinical, veterinary, and domestic preparedness testing.

Tetracore, Inc.

CONTACT: Barry Michael of Tetracore, Inc., +1-301-258-7553 x 224



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES